Cell metabolism

The role of GIP receptor signaling in regulating the body's energy balance

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Incretin receptor agonists have been effective in combatting obesity and diabetes.

  • GLP-1 receptor agonists have established roles in managing obesity and diabetes.
  • Adipose tissue's GIP receptor may influence energy balance and weight regulation.
  • Understanding the effects of GIP receptor agonists is limited compared to GLP-1 receptor agonists.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declaration of interests The authors declare no competing interests.
PubMed

Related papers

Jul '24
How Incretin Hormones Help Regulate Heart Energy Use
cited by 1 paper
journal article
Dec '20
Targeting the GIP receptor for obesity: Should it be activated or blocked? Possible ways it works
top 5% journal
cited by 124 papers
research support, n.i.h., extramural
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article
Apr '25
How GIPR influences the control of food intake
top 10% journal
cited by 15 papers
journal article
Dec '20
Genetic changes and selective drugs that reduce β-arrestin increase cAMP signals at glucagon-related receptors
top 10% journal
cited by 91 papers
research support, non-u.s. gov't
Mar '24
Control of body energy use through brain GIP receptor signals
cited by 14 papers
research support, non-u.s. gov't
Feb '25
Mice missing one incretin receptor do not increase secretion of the other hormone after glucose
top 10% journal
journal article
May '24
Less movement of incretin receptors after activation improves blood sugar control and reverses obesity in diet-induced obese mice
cited by 2 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
yesterday7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
1 week ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
2 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
3 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
4 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
5 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
6 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
7 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
8 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief